JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?

被引：0
|
作者：
S Verstovsek
R T Silver
N C P Cross
A Tefferi
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Leukemia
[2] Leukemia and Myeloproliferative Center,Division of Hematology
[3] Weill Medical College of Cornell University,undefined
[4] Wessex Regional Genetics Laboratory,undefined
[5] Salisbury District Hospital,undefined
[6] Mayo Clinic College of Medicine,undefined
来源：
Leukemia | 2006年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2067 / 2067
相关论文
共 50 条
  • [21] Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth
    Li, Zhe
    Xu, Mingjiang
    Xing, Shu
    Ho, Wanting Tina
    Ishii, Takefumi
    Li, Qingshan
    Fu, Xueqi
    Zhao, Zhizhuang Joe
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (06) : 3428 - 3432
  • [22] JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia
    Randi, Maria Luigia
    Ruzzon, Elisabetta
    Tezza, Fabiana
    Scapin, Margherita
    Duner, Elena
    Scandellari, Raffaella
    Fabris, Fabrizio
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2011, 23 (01) : 17 - 21
  • [23] The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera
    Falchi, Mario
    Varricchio, Lilian
    Martelli, Fabrizio
    Marra, Manuela
    Picconi, Orietta
    Tafuri, Agostino
    Girelli, Gabriella
    Uversky, Vladimir N.
    Migliaccio, Anna Rita
    EXPERIMENTAL HEMATOLOGY, 2017, 50 : 53 - 76
  • [24] Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera
    Tefferi, A.
    Strand, J. J.
    Lasho, T. L.
    Knudson, R. A.
    Finke, C. M.
    Gangat, N.
    Pardanani, A.
    Hanson, C. A.
    Ketterling, R. P.
    LEUKEMIA, 2007, 21 (09) : 2074 - 2075
  • [25] Detection of JAK2V617F used for diagnosis of polycythemia vera and correlation with other biomarkers
    Daniels, L.
    Vermeulen, K.
    Van De Velde, A. L.
    Vrelust, I.
    Gadisseur, A. P.
    Schroyens, W.
    Berneman, Z. N.
    ACTA CLINICA BELGICA, 2007, 62 (04): : 262 - 262
  • [26] THROMBOSIS IN POLYCYTHEMIA VERA ARE LIKELY TO BE RELATED TO HIGHER JAK2V617F ALLELE BURDEN
    Bertozzi, I.
    Scapin, M.
    Tezza, F.
    Scandellari, R.
    Fabris, F.
    Randi, M. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 361 - 361
  • [27] Extent of hematopoietic involvement by TET2 mutations in JAK2V617F polycythemia vera
    Swierczek, Sabina I.
    Yoon, Donghoon
    Bellanne-Chantelot, Christine
    Kim, Soo Jin
    Saint-Martin, Cecile
    Delhommeau, Francois
    Najman, Albert
    Prchal, Josef T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (05): : 775 - 778
  • [28] JAK2V617F mutational load in patients with Polycythemia Vera (PV) measured by peripheral blood DNA is associated with disease severity
    Silver, Richard T.
    Vandris, Katherine
    Wang, Y. Lynn
    Christos, Paul J.
    Adriano, Fernando
    Jones, Amy V.
    Cross, Nicholas C. P.
    BLOOD, 2007, 110 (11) : 746A - 746A
  • [29] JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera
    Carobbio, Alessandra
    Finazzi, Guido
    Antonioli, Elisabetta
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    Dellacasa, Chiara M.
    Salmoiraghi, Silvia
    Delaini, Federica
    Rambaldi, Alessandro
    Barbui, Tiziano
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (09) : 1016 - 1021
  • [30] The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
    Tefferi, A
    Lasho, TL
    Schwager, SM
    Strand, JS
    Elliott, M
    Mesa, R
    Li, CY
    Wadleigh, M
    Lee, SJ
    Gilliland, DG
    CANCER, 2006, 106 (03) : 631 - 635
12345